Maximum Civil Money Penalty Amounts; Civil Money Penalty Complaints
Federal Register, Volume 79 Issue 22 (Monday, February 3, 2014)
Federal Register Volume 79, Number 22 (Monday, February 3, 2014)
Rules and Regulations
Pages 6088-6092
From the Federal Register Online via the Government Printing Office www.gpo.gov
FR Doc No: 2014-02150
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Docket No. FDA-2014-N-0113
Maximum Civil Money Penalty Amounts; Civil Money Penalty Complaints
AGENCY: Food and Drug Administration, HHS.
ACTION: Direct final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is issuing a new regulation to adjust for inflation the maximum civil money penalty (CMP) amounts for the various CMP authorities within our jurisdiction and to amend the process for initiating certain CMP
Page 6089
administrative actions. We are taking these actions to comply with the Federal Civil Penalties Inflation Adjustment Act of 1990 (FCPIAA), as amended, and to streamline our internal processes. The last CMP adjustment was published in the Federal Register of November 12, 2008, and the FCPIAA requires Federal Agencies to adjust their CMPs at least once every 4 years. We are using direct final rulemaking for these actions because the Agency expects that there will be no significant adverse comment on the rule. We are concurrently proposing and soliciting comments on this rule. If significant adverse comments are received, we will withdraw this final rule and address the comments in a subsequent final rule. FDA will not provide additional opportunity for comment.
DATES: This rule is effective June 18, 2014, without further notice, unless FDA receives significant adverse comment by April 21, 2014. If we receive no timely significant adverse comments, we will publish a document in the Federal Register before May 19, 2014, confirming the effective date of the direct final rule. If we receive any timely significant adverse comments, we will publish a document in the Federal Register withdrawing this direct final rule before June 18, 2014.
ADDRESSES: You may submit comments, identified by Docket No. FDA-2014-
N-0113, by any of the following methods.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: http://www.regulations.gov. Follow the instructions for submitting comments.
Written Submissions
Submit written submissions in the following ways:
Mail/Hand delivery/Courier (for paper submissions): Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
Instructions: All submissions received must include the Agency name and Docket No. FDA-2014-N-0113 for this rulemaking. All comments received may be posted without change to http://www.regulations.gov, including any personal information provided. For additional information on submitting comments, see the ``Comments'' heading of the SUPPLEMENTARY INFORMATION section of this document.
Docket: For access to the docket to read background documents or comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ``Search'' box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Jarilyn Dupont, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20903, 301-796-4830.
SUPPLEMENTARY INFORMATION: The last CMP adjustment was published in the Federal Register of November 12, 2008 (73 FR 66750).
-
Background
-
CMP Amounts
FDA is amending Sec. 17.2 (21 CFR 17.2) to update the maximum CMP amounts. In general, FCPIAA requires Federal Agencies to issue regulations to adjust for inflation each CMP penalty provided by law within their jurisdiction. (28 U.S.C. 2461 note, as amended by the Debt Collection Improvement Act of 1996 (31 U.S.C. 3701)). FCPIAA directs Agencies to adjust the CMP provided by law by October 23, 1996, and to make additional adjustments at least once every 4 years thereafter. The adjustments are based on changes in the cost of living, and the FCPIAA defines the cost of living adjustment as the percentage (if any) for each civil monetary penalty by which the Consumer Price Index for the month of June of the calendar year preceding the adjustment, exceeds the Consumer Price Index for the month of June of the calendar year in which the amount of such civil monetary penalty was last set or adjusted pursuant to law (28 U.S.C. 2461 note, section 5(b)).
FCPIAA also prescribes a rounding method based on the size of the penalty after the calculated increase, but states that the adjustment of a CMP may not exceed 10 percent of the penalty. FCPIAA defines a CMP as any penalty, fine, or other sanction that is for a specific monetary amount as provided by Federal law; or has a maximum amount provided for by Federal law; and is assessed or enforced by an agency pursuant to Federal law; and is assessed or enforced pursuant to an administrative proceeding or a civil action in the Federal Courts (28 U.S.C. 2461 note, section 3(2)).
-
CMP Complaints
Currently, under Sec. 17.5(a) (21 CFR 17.5(a)), CMP complaints against retailers of tobacco products may only be signed by attorneys in FDA's Office of the Chief Counsel (OCC). Given the routine nature of many of these CMPs, FDA is amending this regulation to permit the Chief Counsel to designate other FDA staff, such as those in FDA's Center for Tobacco Products, to sign a tobacco retailer CMP complaint.
Based on FDA's experience, the large majority of the tobacco retailer complaints to date have involved alleged violations of the requirement to not sell cigarettes and smokeless tobacco to any person younger than 18 years of age or to verify age in accordance with 21 CFR 1140.14(b). These complaints have almost always been straightforward, they involve simple fact patterns, and they do not require a complex legal analysis. Over time, such CMP complaints have increased in volume, and we anticipate that the volume will continue to be relatively high.
We have determined that, with certain limitations and controls, non-attorney staff outside OCC can carry out the function of reviewing the evidence and signing the tobacco retailer CMP complaints in appropriate circumstances. The proposed amendment to Sec. 17.5(a) would give this decisionmaking authority to the Chief Counsel, who could ensure the authority to sign complaints is only given to appropriate staff and under appropriate circumstances. Under the proposal, the Chief Counsel would have the authority to set and revise limitations and controls, and to broaden, limit, or rescind any authorizations to sign tobacco retailer CMP complaints.
The limitations could include, for example, limiting the delegation to situations where the CMP amount is below a certain dollar value; the CMP involves specified tobacco retailer charges that OCC has determined are routine and predictable and do not require a complex legal analysis; and involve charges for which FDA has developed OCC-approved templates, parameters, and procedures. The controls could include, for example, an audit or other quality review.
FDA is publishing this rule as a direct final rule without prior proposal and comment because we view these as noncontroversial amendments and anticipate no significant adverse comment. This rule incorporates requirements specifically set forth in the FCPIAA requiring FDA to issue a regulation implementing inflation adjustments for all its CMP provisions. These technical changes, required by law, do not substantively alter the existing regulatory framework, nor do they in any way affect the terms under which CMPs are assessed by FDA. The formula for the amount of the penalty
Page 6090
adjustment is prescribed by Congress in the FCPIAA, and these changes are not subject to the exercise of discretion by FDA. The amendment to Sec. 17.5(a) changes an internal process.
This direct final rule:
Revises the table in Sec. 17.2 to adjust the maximum CMP amounts for inflation as prescribed by FCPIAA.
Revises Sec. 17.5(a) to provide authority for the Chief Counsel to delegate the responsibility for initiating a CMP administrative action against a tobacco retailer.
-
-
Environmental Impact
The Agency has determined under 21 CFR 25.33 that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.
-
Paperwork Reduction Act
This final rule contains no collection of information. Therefore, clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995 is not required.
-
Federalism
FDA has analyzed this final rule in accordance with the principles set forth in Executive Order 13132. FDA has determined that the rule does not contain policies that have substantial direct effects on the States, on the relationship between the National Government and the States, or on the distribution of power and responsibilities among the various levels of government. Accordingly, the Agency has concluded that the rule does not contain policies that have federalism implications as defined in the Executive order and, consequently, a federalism summary impact statement is not required.
-
Analysis of Impacts
FDA has examined the impacts of the final rule under Executive Order 12866, Executive Order 13563, the Regulatory Flexibility Act (5 U.S.C. 601-612), and the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4). Executive Orders 12866 and 13563 direct Agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety, and other advantages; distributive impacts; and equity). The Agency believes that this final rule is not a significant regulatory action under Executive Order 12866.
The Regulatory Flexibility Act requires Agencies to analyze regulatory options that would minimize any significant impact of a rule on small entities. Because the final rule simply adjusts the maximum amount of CMPs administered by FDA as required by the FCPIAA, and because the proposed rule makes a change to FDA's internal processes, the Agency certifies that the final rule will not have a significant economic impact on a substantial number of small entities.
Section 202(a) of the Unfunded Mandates Reform Act of 1995 requires that Agencies prepare a written statement, which includes an assessment of anticipated costs and benefits, before proposing ``any rule that includes any Federal mandate that may result in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of $100,000,000 or more (adjusted annually for inflation) in any one year.'' The current threshold after adjustment for inflation is $141 million, using the most current (2012) Implicit Price Deflator for the Gross Domestic Product. FDA does not expect this final rule to result in any 1-year expenditure that would meet or exceed this amount.
-
Comments
Interested persons may submit either electronic comments regarding this document to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.
List of Subjects in 21 CFR Part 17
Administrative practice and procedure, Penalties.
Therefore, under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 17 is amended as follows:
PART 17--CIVIL MONEY PENALTIES HEARINGS
0
-
The authority citation for 21 CFR part 17 continues to read as follows:
Authority: 21 U.S.C. 331, 333, 337, 351, 352, 355, 360, 360c, 360f, 360i, 360j, 371; 42 U.S.C. 262, 263b, 300aa-28; 5 U.S.C. 554, 555, 556, 557.
0
-
Section 17.2 is revised to read as follows:
Sec. 17.2 Maximum penalty amounts.
The following table shows maximum civil monetary penalties associated with the statutory provisions authorizing civil monetary penalties under the Federal Food, Drug, and Cosmetic Act or the Public Health Service Act.
Civil Monetary Penalties Authorities Administered by FDA and Adjusted Maximum Penalty Amounts
----------------------------------------------------------------------------------------------------------------
Former
maximum Date of last Adjusted maximum
U.S.C. Section penalty Assessment method penalty figure penalty amount (in
amount (in or adjustment dollars)
dollars)
----------------------------------------------------------------------------------------------------------------
21 U.S.C.
----------------------------------------------------------------------------------------------------------------
333(b)(2)(A)..................... 60,000 For each of the first 2013 65,000.
two violations in any
10-year period.
333(b)(2)(B)..................... 1,200,000 For each violation after 2013 1,275,000.
the second conviction
in any 10-year period.
333(b)(3)........................ 120,000 Per violation........... 2013 130,000.
333(f)(1)(A)..................... 16,500 Per violation........... 2008 16,500 (not
adjusted).
333(f)(1)(A)..................... 1,200,000 For the aggregate of 2013 1,275,000.
violations.
333(f)(2)(A)..................... 55,000 Per individual.......... 2013 60,000.
333(f)(2)(A)..................... 300,000 Per ``any other person'' 2013 325,000.
333(f)(2)(A)..................... 600,000 For all violations 2013 650,000.
adjudicated in a single
proceeding.
Page 6091
333(f)(3)(A)..................... 10,000 For all violations 2013 11,000.
adjudicated in a single
proceeding.
333(f)(3)(B)..................... 10,000 For each day the 2013 11,000.
violation is not
corrected after a 30-
day period following
notification until the
violation is corrected.
333(f)(4)(A)(i).................. 250,000 Per violation........... 2013 275,000.
333(f)(4)(A)(i).................. 1,000,000 For all violations 2013 1,075,000.
adjudicated in a single
proceeding.
333(f)(4)(A)(ii)................. 250,000 For the first 30-day 2013 275,000.
period (or any portion
thereof) of continued
violation following
notification.
333(f)(4)(A)(ii)................. 1,000,000 For any 30-day period, 2013 1,075,000.
where the amount
doubles for every 30-
day period of continued
violation after the
first 30-day violation.
333(f)(4)(A)(ii)................. 10,000,000 For all violations 2013 10,850,000.
adjudicated in a single
proceeding.
333(f)(9)(A)..................... 15,000 Per violation........... 2009 15,000 (not
adjusted).
333(f)(9)(A)..................... 1,000,000 For all violations 2013 1,050,000.
adjudicated in a single
proceeding.
333(f)(9)(B)(i)(I)............... 250,000 Per violation........... 2013 275,000.
333(f)(9)(B)(i)(I)............... 1,000,000 For all violations 2013 1,050,000.
adjudicated in a single
proceeding.
333(f)(9)(B)(i)(II).............. 250,000 For the first 30-day 2013 275,000.
period (or any portion
thereof) of continued
violation following
notification.
333(f)(9)(B)(i)(II).............. 1,000,000 For any 30-day period, 2013 1,050,000.
where the amount
doubles for every 30-
day period of continued
violation after the
first 30-day violation.
333(f)(9)(B)(i)(II).............. 10,000,000 For all violations 2013 10,525,000.
adjudicated in a single
proceeding.
333(f)(9)(B)(ii)(I).............. 250,000 Per violation........... 2013 275,000.
333(f)(9)(B)(ii)(I).............. 1,000,000 For all violations 2013 1,050,000.
adjudicated in a single
proceeding.
333(f)(9)(B)(ii)(II)............. 250,000 For the first 30-day 2013 275,000.
period (or any portion
thereof) of continued
violation following
notification.
333(f)(9)(B)(ii)(II)............. 1,000,000 For any 30-day period, 2013 1,050,000.
where the amount
doubles for every 30-
day period of continued
violation after the
first 30-day violation.
333(f)(9)(B)(ii)(II)............. 10,000,000 For all violations 2013 10,525,000.
adjudicated in a single
proceeding.
333(g)(1)........................ 250,000 For the first violation 2013 275,000.
in any 3-year period.
333(g)(1)........................ 500,000 For each subsequent 2013 550,000.
violation in any 3-year
period.
333 note......................... 250 For the second violation 2009 250 (not adjusted).
(following a first
violation with a
warning) within a 12-
month period by a
retailer with an
approved training
program.
333 note......................... 500 For the third violation 2009 500 (not adjusted).
within a 24-month
period by a retailer
with an approved
training program.
333 note......................... 2,000 For the fourth violation 2009 2,000 (not
within a 24-month adjusted).
period by a retailer
with an approved
training program.
333 note......................... 5,000 For the fifth violation 2009 5,000 (not
within a 36-month adjusted).
period by a retailer
with an approved
training program.
333 note......................... 10,000 For the sixth or 2013 11,000.
subsequent violation
within a 48-month
period by a retailer
with an approved
training program.
333 note......................... 250 For the first violation 2009 250 (not adjusted).
by a retailer without
an approved training
program.
333 note......................... 500 For the second violation 2009 500 (not adjusted).
within a 12-month
period by a retailer
without an approved
training program.
333 note......................... 1,000 For the third violation 2013 1,100.
within a 24-month
period by a retailer
without an approved
training program.
333 note......................... 2,000 For the fourth violation 2009 2,000 (not
within a 24-month adjusted).
period by a retailer
without an approved
training program.
333 note......................... 5,000 For the fifth violation 2009 5,000 (not
within a 36-month adjusted).
period by a retailer
without an approved
training program.
333 note......................... 10,000 For the sixth or 2013 11,000.
subsequent violation
within a 48-month
period by a retailer
without an approved
training program.
335b(a).......................... 300,000 Per violation for an 2013 325,000.
individual.
335b(a).......................... 1,200,000 Per violation for ``any 2013 1,275,000.
other person''.
360pp(b)(1)...................... 1,100 Per violation per person 2008 1,100 (not
adjusted).
360pp(b)(1)...................... 355,000 For any related series 2013 375,000.
of violations.
----------------------------------------------------------------------------------------------------------------
42 U.S.C.
----------------------------------------------------------------------------------------------------------------
263b(h)(3)....................... 11,000 Per violation........... 2008 11,000 (not
adjusted).
300aa-28(b)(1)................... 120,000 Per occurrence.......... 2013 130,000.
----------------------------------------------------------------------------------------------------------------
Page 6092
0
-
In Sec. 17.5, revise paragraph (a) to read as follows:
Sec. 17.5 Complaint.
(a) The Center with principal jurisdiction over the matter involved shall begin all administrative civil money penalty actions by serving on the respondent(s) a complaint signed by the Office of the Chief Counsel attorney for the Center and by filing a copy of the complaint with the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. For a civil money penalty action against retailers of tobacco products, the complaint may be signed by any Agency employee designated by the Chief Counsel.
* * * * *
Dated: January 28, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
FR Doc. 2014-02150 Filed 1-31-14; 8:45 am
BILLING CODE 4160-01-P
-
